ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol

ZELYURT, SERDAL; MARAL, IŞIL; Sürmeli, Aral; kural, kemal; ALKAN, Perihan; memisoglu, kemal; ŞAHİN, ESRA; YILMAZ, HABİP; GÜNER, ABDULLAH EMRE; Kazezoğlu, Cemal; KOCAYİĞİT, Erdoğan

doi:10.14744/nci.2021.60420

ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol

Abdullah Emre GÜNER, (İstanbul Sağlık Müdürlüğü, Halk Sağlığı Hizmetleri, İstanbul, Türkiye)

Aral SÜRMELİ, (Türkiye Tıbbi Kurtarma Derneği, İstanbul, Türkiye)

Kemal KURAL, (İstanbul Sağlık Müdürlüğü, İzleme, Değerlendirme ve İstatistik, İstanbul, Türkiye)

Habip YILMAZ, (İstanbul Sağlık Müdürlüğü, Kamu Hastane Hizmetleri Daire Başkanlığı, İstanbul, Türkiye)

Erdoğan KOCAYİĞİT, (İstanbul Sağlık Müdürlüğü, Halk Sağlığı Hizmetleri, İstanbul, Türkiye)

Esra SAHİN, (İstanbul Sağlık Müdürlüğü, Halk Sağlığı Hizmetleri, İstanbul, Türkiye)

Perihan ALKAN, (İstanbul Sağlık Müdürlüğü, Enfeksiyon Hastalıkları, İstanbul, Türkiye)

Cemal KAZEZOĞLU, (Sağlık Bilimleri Üniversitesi, Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi, İstanbul, Türkiye)

Serdal ZELYURT, (İstanbul Sağlık Müdürlüğü, Destek Hizmetleri, İstanbul, Türkiye)

Kemal MEMİŞOĞLU, (İstanbul Sağlık Müdürlüğü, Sağlık Müdürü, İstanbul, Türkiye)

Işıl MARAL, (İstanbul Medeniyet Üniversitesi Tıp Fakültesi Halk Sağlığı Anabilim Dalı, İstanbul, Türkiye)

Diğer Yazarlar

İstanbul Kuzey Klinikleri

5 2

Yıl: 2021 Cilt: 8 Sayı: 2 Sayfa Aralığı: 119 - 123 Metin Dili: İngilizce DOI: 10.14744/nci.2021.60420 İndeks Tarihi: 09-05-2021

ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol

Öz:

OBJECTIVE: The objective of this study was to understand the observational relationship between adoption of favipiravir into the national COVID-19 treatment protocol and intensive care unit (ICU) admission rates in Istanbul due to COVID-19.METHODS: Data were harvested from the “Public Health Management System-HSYS,” which collate centrally the records of all known cases of COVID-19. The total number of cases, numbers admitted to ICU, and number undergoing intubation were compared between 2 time periods: 11th of March, the date on which the first case in Turkey was confirmed, to 30th of March; and March 30, to 10th of April, 5 days after Favipiravir was introduced into the treatment algorithm when, the records were examined.RESULTS: The percentage of patients requiring ICU admission diminished from 24% to 12%, whilst the percentage intubated fell from 77% to 66%. These differences were both statistically significant.CONCLUSION: The addition of favipiravir to the national COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.
2. Coronavirus Update (Live): 6,513,890 cases and 384,642 deaths from COVID-19 virus pandemic - Worldometer (Internet). Available at: https://www.worldometers.info/coronavirus/. Accessed Jun 3, 2020.
3. COVID-19 - Yeni koronavirüs hastalığı (new coronavirus disease) (Internet). Available at: https://covid19bilgi.saglik.gov.tr/tr. Accessed Jun 2, 2020.
4. Pandemik influenza ulusal hazırlık planı (National pandemic influenza preparedness plan). Ankara: Ministry of Health of Turkey, Public Health Directorate; 2019. Available at: https://hsgm.saglik.gov.tr/tr/ bulasicihastaliklar-haberler/ulusal-pandemi-hazirlik-plani.html. Accessed May 25, 2020.
5. Algoritmalar C. COVID-19 Algoritmalar (COVID-19 Treatment Protocol- Version 1). Available at: https://covid19bilgi.saglik.gov.tr/ tr/algoritmalar. Accessed Jan 30, 2020.
6. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:449–63.
7. Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. J Chin Med Assoc 2020;83:534–6.
8. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58–60.
9. Algoritmalar C. COVID-19 Algoritmalar (COVID-19 Treatment Protocol- Version 6). Available at: https://covid19bilgi.saglik.gov.tr/ tr/algoritmalar. Accessed Mar 25, 2020.
10. World Health Organization. Surveillance, rapid response teams, and case investigation. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/surveillance-andcase-definitions. Accessed May 18, 2020.
11. Microsoft Corporation. Microsoft Excel (Internet). 2018. Available at: https://office.microsoft.com/excel. Accessed Feb 24, 2021.
12. IBM Corp. IBM SPSS Statistics for Windows (Internet). Armonk, NY: IBM Corp; 2017. Available at: https://hadoop.apache.org. Accessed Feb 24, 2021.
13. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020;6:1192–8.
14. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARSCoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574–81.
15. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020;81:e16–25

APA	GÜNER A, Sürmeli A, kural k, YILMAZ H, KOCAYİĞİT E, ŞAHİN E, ALKAN P, Kazezoğlu C, ZELYURT S, memisoglu k, MARAL I (2021). ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. , 119 - 123. 10.14744/nci.2021.60420
Chicago	GÜNER ABDULLAH EMRE,Sürmeli Aral,kural kemal,YILMAZ HABİP,KOCAYİĞİT Erdoğan,ŞAHİN ESRA,ALKAN Perihan,Kazezoğlu Cemal,ZELYURT SERDAL,memisoglu kemal,MARAL IŞIL ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. (2021): 119 - 123. 10.14744/nci.2021.60420
MLA	GÜNER ABDULLAH EMRE,Sürmeli Aral,kural kemal,YILMAZ HABİP,KOCAYİĞİT Erdoğan,ŞAHİN ESRA,ALKAN Perihan,Kazezoğlu Cemal,ZELYURT SERDAL,memisoglu kemal,MARAL IŞIL ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. , 2021, ss.119 - 123. 10.14744/nci.2021.60420
AMA	GÜNER A,Sürmeli A,kural k,YILMAZ H,KOCAYİĞİT E,ŞAHİN E,ALKAN P,Kazezoğlu C,ZELYURT S,memisoglu k,MARAL I ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. . 2021; 119 - 123. 10.14744/nci.2021.60420
Vancouver	GÜNER A,Sürmeli A,kural k,YILMAZ H,KOCAYİĞİT E,ŞAHİN E,ALKAN P,Kazezoğlu C,ZELYURT S,memisoglu k,MARAL I ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. . 2021; 119 - 123. 10.14744/nci.2021.60420
IEEE	GÜNER A,Sürmeli A,kural k,YILMAZ H,KOCAYİĞİT E,ŞAHİN E,ALKAN P,Kazezoğlu C,ZELYURT S,memisoglu k,MARAL I "ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol." , ss.119 - 123, 2021. 10.14744/nci.2021.60420
ISNAD	GÜNER, ABDULLAH EMRE vd. "ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol". (2021), 119-123. https://doi.org/10.14744/nci.2021.60420

APA	GÜNER A, Sürmeli A, kural k, YILMAZ H, KOCAYİĞİT E, ŞAHİN E, ALKAN P, Kazezoğlu C, ZELYURT S, memisoglu k, MARAL I (2021). ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. İstanbul Kuzey Klinikleri, 8(2), 119 - 123. 10.14744/nci.2021.60420
Chicago	GÜNER ABDULLAH EMRE,Sürmeli Aral,kural kemal,YILMAZ HABİP,KOCAYİĞİT Erdoğan,ŞAHİN ESRA,ALKAN Perihan,Kazezoğlu Cemal,ZELYURT SERDAL,memisoglu kemal,MARAL IŞIL ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. İstanbul Kuzey Klinikleri 8, no.2 (2021): 119 - 123. 10.14744/nci.2021.60420
MLA	GÜNER ABDULLAH EMRE,Sürmeli Aral,kural kemal,YILMAZ HABİP,KOCAYİĞİT Erdoğan,ŞAHİN ESRA,ALKAN Perihan,Kazezoğlu Cemal,ZELYURT SERDAL,memisoglu kemal,MARAL IŞIL ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. İstanbul Kuzey Klinikleri, vol.8, no.2, 2021, ss.119 - 123. 10.14744/nci.2021.60420
AMA	GÜNER A,Sürmeli A,kural k,YILMAZ H,KOCAYİĞİT E,ŞAHİN E,ALKAN P,Kazezoğlu C,ZELYURT S,memisoglu k,MARAL I ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. İstanbul Kuzey Klinikleri. 2021; 8(2): 119 - 123. 10.14744/nci.2021.60420
Vancouver	GÜNER A,Sürmeli A,kural k,YILMAZ H,KOCAYİĞİT E,ŞAHİN E,ALKAN P,Kazezoğlu C,ZELYURT S,memisoglu k,MARAL I ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol. İstanbul Kuzey Klinikleri. 2021; 8(2): 119 - 123. 10.14744/nci.2021.60420
IEEE	GÜNER A,Sürmeli A,kural k,YILMAZ H,KOCAYİĞİT E,ŞAHİN E,ALKAN P,Kazezoğlu C,ZELYURT S,memisoglu k,MARAL I "ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol." İstanbul Kuzey Klinikleri, 8, ss.119 - 123, 2021. 10.14744/nci.2021.60420
ISNAD	GÜNER, ABDULLAH EMRE vd. "ICU admission rates in Istanbul following theaddition of favipiravir to the national COVID-19treatment protocol". İstanbul Kuzey Klinikleri 8/2 (2021), 119-123. https://doi.org/10.14744/nci.2021.60420